

Letter to the Editor

Comment on “Investigation of the Optimal Interval of Perioperative Serum Flomoxef Administration in Hepatobiliary-Pancreatic Surgery”

Ugne Silinskaite¹, Jun Hirai², Akihisa Matsuda³,
Tomas Poskus⁴, Hiroshi Yoshida³

¹Faculty of Medicine, Vilnius University, Vilnius, Lithuania

²Division of Infection Control and Prevention, Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan

³Department of Gastroenterological Surgery, Nippon Medical School, Tokyo, Japan

⁴Institute of Translational Health Research, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

To the Editor:

We have read with great interest the recent article by Takayama et al.¹ entitled “Investigation of the Optimal Interval of Perioperative Serum Flomoxef Administration in Hepatobiliary-Pancreatic Surgery” published in Journal of Nippon Medical School.

This study offers valuable contributions toward determining the optimal perioperative dosing schedule of flomoxef (FMOX) in hepatobiliary and pancreatic surgeries (HBP). The authors analyse and highlight the connection between FMOX serum concentrations and creatinine clearance. These findings address a major gap in the current literature—namely, the absence of pharmacokinetic-based dosing recommendations for FMOX in HBP surgery patients, especially in those with impaired renal function. Assessing creatinine clearance enables optimal dosing and helps prevent both underdosing and overdosing, which may lead to surgical site infections (SSIs) or adverse drug effects.

However, I would like to raise several points for further discussion. To begin with, the study sample size is relatively small—only 31 patients were included. As a result, the statistical power to detect significant differences may be limited. While the findings are valuable, it is highly recommended to confirm them in larger, multicenter studies. The study was conducted in a single-center setting with a limited patient population; therefore, the external validity of the results may be limited and caution is needed when generalizing the findings. Additionally, free FMOX

concentration data was not measured in the study. This is unfortunate, as this parameter is generally more accurate in reflecting the pharmacological effect of the drug than total serum FMOX concentration.

In this study, FMOX administration for HBP surgery was not compared with other prophylactic antibiotics. Previous research has shown comparable SSI rates between cefmetazole and FMOX in colorectal surgery, with cefmetazole even reducing organ/space SSI risk and hospitalization costs compared to FMOX². In vitro data suggest that FMOX may have superior activity against pathogens such as *Escherichia coli* and *Klebsiella pneumoniae*, with MIC ≤ 1 $\mu\text{g/mL}$ observed in up to 97–100% of *E. coli* and 80–100% of *K. pneumoniae*, compared with lower percentages for cefmetazole³. Meanwhile, studies comparing levofloxacin and FMOX found no significant difference in bacterial resistance, though levofloxacin showed slower changes in resistance patterns⁴. These findings highlight the need for a concise comparative analysis of FMOX with cefmetazole and levofloxacin in HBP surgery prophylaxis to establish evidence-based prophylactic dosing strategies and antibiotic selection guidelines.

Although this study focused exclusively on adult patients undergoing HBP surgery, the lack of pharmacokinetic data for FMOX in pediatric HBP surgery also suggests an area for future investigation. For now, it is known that FMOX is effective in treating urinary tract infections in children⁵. Older literature from 1987⁶ also found FMOX to be useful in treating other general pediatric infections such as pneumonia, pyothorax, staphylococcal scalded skin syndrome, cellulitis, and arthritis. However, further studies are warranted to establish safe and effective dosing in this population.

In conclusion, this study provides valuable insights into FMOX prophylactic dosage in HBP surgery. To further support these findings, it would be helpful to conduct a larger and more detailed study, ideally including a comparative analysis of different antibiotic prophylaxis strategies in both pediatric and adult HBP surgery.

Correspondence to Jun Hirai, j-hirai@nms.ac.jp
https://doi.org/10.1272/jnms.JNMS.2026_93-203

Copyright © 2026 The Medical Association of Nippon Medical School. This is an open access article under the CC BY-NC-ND 4.0 license (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Acknowledgments: None.

Funding: None.

Conflict of Interest: The authors declared that they have no competing interests.

Declaration of Generative AI and AI-Assisted Technologies in the Writing Process: The authors declare that no generative AI or AI-assisted technologies were used in the preparation, writing, or editing of this manuscript.

References

1. Takayama Y, Komatsu T, Tsumuraya S, et al. Investigation of the optimal interval of perioperative serum flomoxef administration in hepatobiliary-pancreatic surgery. *J Nippon Med Sch.* 2025;92(2):196–203. doi: 10.1272/jnms.JNMS.2025_92-211. PubMed PMID: 40399116
2. Urano Y, Saito S, Machimoto T, et al. Differences in clinical and cost-effectiveness between cefmetazole and flomoxef for the prevention of surgical site infection in elective colorectal surgery: A single-center, retrospective cohort study. *J Infect Chemother.* 2022 Apr;28(4):510–5. doi: 10.1016/j.jiac.2021.12.023. Epub 2022 Jan 10. PubMed PMID: 35016825
3. Iio K, Hagiya H, Higashionna T, Otsuka F. In vitro activity of cefmetazole and flomoxef among extended-spectrum beta-lactamase producing Enterobacterales. *New Microbiol.* 2024 Jan;46(4):348–53. PubMed PMID: 38252045
4. Inoshita A, Yokoi H, Matsumoto F, et al. A randomized prospective study of oral levofloxacin vs intravenous flomoxef prophylaxis in postoperative infection after endoscopic sinus surgery. *Am J Otolaryngol.* 2010 Sep-Oct; 31(5):360–3. doi: 10.1016/j.amjoto.2009.06.001. Epub 2009 Jul 29. PubMed PMID: 20015788
5. Abe Y, Inan-Erdogan I, Fukuchi K, et al. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing *Escherichia coli*. *J Infect Chemother.* 2017 Aug;23(8):517–22. doi: 10.1016/j.jiac.2017.04.006. Epub 2017 May 18. PubMed PMID: 28528936
6. Kuroki S, Haruta T, Tsutsui T, et al. [Bacteriological and clinical studies of flomoxef in the pediatric field]. *Jpn J Antibiot.* 1987 Aug;40(8):1447–61. Japanese. PubMed PMID: 3430720